According to Zacks, “MacroGenics Inc. is a biopharmaceutical company. It is focused on discovering and developing innovative monoclonal antibody-based therapeutics. The Company has a diverse portfolio of product candidates focused in three therapeutic areas: oncology, autoimmune disorders and infectious diseases. MacroGenics Inc. is headquartered in Rockville, Maryland. “
MGNX has been the subject of several other reports. Credit Suisse Group restated an underperform rating on shares of MARKS & SPENCER/S in a report on Wednesday, April 17th. Guggenheim cut shares of Anadarko Petroleum from a buy rating to a hold rating and set a $69.00 price target for the company. in a report on Friday, April 12th. ValuEngine cut shares of Intersect ENT from a buy rating to a hold rating in a report on Monday, July 8th. Morgan Stanley restated a top pick rating on shares of in a report on Wednesday, June 5th. Finally, BidaskClub cut shares of Extraction Oil & Gas from a hold rating to a sell rating in a report on Saturday, May 4th. Two investment analysts have rated the stock with a sell rating, four have given a hold rating and nine have assigned a buy rating to the stock. MacroGenics has a consensus rating of Hold and a consensus target price of $31.62.
MacroGenics (NASDAQ:MGNX) last posted its quarterly earnings results on Wednesday, May 1st. The biopharmaceutical company reported ($0.99) EPS for the quarter, missing the consensus estimate of ($0.95) by ($0.04). The company had revenue of $9.66 million for the quarter, compared to analyst estimates of $11.46 million. MacroGenics had a negative return on equity of 57.65% and a negative net margin of 256.47%. As a group, analysts anticipate that MacroGenics will post -3.75 earnings per share for the current fiscal year.
In other MacroGenics news, SVP Eric Blasius Risser sold 3,000 shares of MacroGenics stock in a transaction that occurred on Monday, May 20th. The shares were sold at an average price of $18.38, for a total value of $55,140.00. Following the completion of the sale, the senior vice president now directly owns 33,806 shares in the company, valued at $621,354.28. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Company insiders own 7.88% of the company’s stock.
A number of hedge funds and other institutional investors have recently bought and sold shares of MGNX. Rhumbline Advisers increased its position in shares of MacroGenics by 48.8% during the fourth quarter. Rhumbline Advisers now owns 51,665 shares of the biopharmaceutical company’s stock worth $656,000 after purchasing an additional 16,950 shares in the last quarter. Prudential Financial Inc. acquired a new position in shares of MacroGenics during the fourth quarter worth $965,000. Acadian Asset Management LLC acquired a new position in shares of MacroGenics during the fourth quarter worth $65,000. BlackRock Inc. increased its position in shares of MacroGenics by 5.5% in the 4th quarter. BlackRock Inc. now owns 3,401,391 shares of the biopharmaceutical company’s stock valued at $43,198,000 after acquiring an additional 176,135 shares during the period. Finally, Citigroup Inc. increased its position in shares of MacroGenics by 32.4% in the 4th quarter. Citigroup Inc. now owns 52,484 shares of the biopharmaceutical company’s stock valued at $667,000 after acquiring an additional 12,844 shares during the period. Hedge funds and other institutional investors own 90.52% of the company’s stock.
MacroGenics, Inc, a biopharmaceutical company, discovers and develops antibody-based therapeutics for the treatment of cancer in the United States. Its pipeline of immuno-oncology product candidates includes Margetuximab, a monoclonal antibody, which is in Phase III clinical trial that targets HER2-expressing tumors, such as various breast and gastroesophageal cancers.
Further Reading: What strategies should day traders use to execute a trade?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for MacroGenics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MacroGenics and related companies with MarketBeat.com's FREE daily email newsletter.